Spinal cord injury-induced immude deficiency Syndrome: Natuarl killer (NK) cell functionality after spinal cord injury
- Conditions
- G82Paraplegia and tetraplegia
- Registration Number
- DRKS00009855
- Lead Sponsor
- Charité Campus Charité Mitte
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 67
Patients with acute isolated spinal cord injury (AIS A-D) planned
for surgical stabilization and decompression, lesion may include
more than 1 segment
- Patients with acute isolated spinal fracture planned for surgical
stabilization, lesion may include more than 1 segment
- = 2 spinal cord or vertebral lesions definable one from another
- Documented informed consent of the patient
- Non-traumatic spinal cord injury
- 2 or more spinal cord or vertebral lesions definable one from
another
- Severe polytrauma (definition: patients with severe injuries of
life-sustaining organ systems, which per se and in the acute phase
are life-threatening (e.g., severe pelvic trauma, severe body cavity
injuries)
- Concomitant traumatic brain injury (TBI) (definition: i) Patients
with persisting neurological deficit in consequence of the TBI, ii)
patient with severe TBI (Glasgow Coma Scale = 8), and iii) patients
with intracranial pressure monitoring sensors.)
- Neoplasia and/or antineoplastic therapy
- Rheumatic disease, collagenosis, vasculitis or other autoimmune
disease
- Preexisting chronic infectious disease (before the injury)
- Preexisting systemic steroid treatment
- Severe alcohol or drug addiction
- Pregnancy, lactation
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method K cell cytotoxicity (CD107a Expression) nach PMA/ionomycin through Flow Cytometry (FACS) 10 weeks after SCI
- Secondary Outcome Measures
Name Time Method K cell cytokine (IFN-gamma and TNF-alpha) production after PMA/ionomycin Stimulation through flow cytometry (FACS) 10 weeks after SCI